Dabigatran versus warfarin in the treatment of acute venous thromboembolism

摘要: A total of 30 the 1274 patients randomly assigned to receive dabigatran (2.4%), as compared with 27 1265 warfarin (2.1%), had recurrent venous thromboembolism; difference in risk was 0.4 percentage points (95% confidence interval [CI], −0.8 1.5; P<0.001 for prespecified noninferiority margin). The hazard ratio 1.10 CI, 0.65 1.84). Major bleeding episodes occurred 20 (1.6%) and 24 (1.9%) (hazard dabigatran, 0.82; 95% 0.45 1.48), any were observed 205 (16.1%) 277 (21.9%; 0.71; 0.59 0.85). numbers deaths, acute coronary syndromes, abnormal liver-function tests similar two groups. Adverse events leading discontinuation study drug 9.0% 6.8% (P = 0.05). Conclusions For treatment thromboembolism, a fixed dose is effective warfarin, has safety profile that does not require laboratory monitoring. (ClinicalTrials.gov number, NCT00291330.)